Papiloxyl AHCC® 180 capsules. Eliminates the human papillomavirus

Information of Papiloxyl AHCC® 180 capsules. Eliminates the human papillomavirus

These produce a modulating effect on the immune system, increase the concentration of T and B lymphocytes, stimulate the activity of macrophages, thus reinforcing the body's defenses against the action of viruses, bacteria, parasites or neoplastic cells.

It is important to always maintain a balanced immune system, which can be capable of protecting the body from infections, such as that caused by HPV (human papillomavirus/human defense papillomavirus). In this sense, immunotherapy can be integrated into the global strategy of treating the infection, its objective is to help the immune system in its defense against this disease, to transmit information to the body and "readjust" the immune response.

AHCC ENERGY: It is rich in acidified alpha-glucans and other unique fractions, naturally produced using proprietary culture fractions, naturally produced using a proprietary culture process. Due to its superior clinical research support, AHCC is used by hundreds of people worldwide.

AHCC ENERGY: Each capsule contains 500 mg of AHCC plus vitamin C that helps better assimilate AHCC bioactives.

𝗔𝗛𝗖𝗖 𝗕𝗬 𝗣𝗔𝗣𝗜𝗟𝗢𝗫𝗬𝗟:: This supplement is based on the latest study by the Department of Obstetrics, Gynecology and Reproductive Sciences at UTHeath McGovern. Houston, Texas. AHCC® has been the subject of over 200 clinical studies conducted primarily in Japan. Research is currently underway at over 150 research centers and university hospitals in Japan and the United States. Since 1994, over 300 physicians and researchers have met each year in Sapporo, Japan for the AHCC Research Partnership Symposium.

𝗣𝗨𝗕𝗟𝗜𝗖𝗔𝗖𝗜𝗢𝗡𝗘: More than 100 universities and research facilities around the world have conducted studies on AHCC and published over 150 academic articles. (Pubmed))

𝗜𝗠𝗠𝗨𝗡𝗜𝗧𝗔𝗥𝗜𝗢 𝗦𝗜𝗦𝗧𝗘𝗠𝗔 𝗜𝗠𝗠𝗨𝗡𝗜𝗧𝗔𝗥𝗜𝗢 It is important to always maintain a balanced immune system that can protect the body.

How to take AHCC Papiloxyl?

Take 3 to 6 capsules daily, 30 minutes before main meals. Suitable for men and women.

How long should I take Papiloxyl AHCC?

It is usually recommended to observe the effectiveness of the supplement and if so, it can be taken at least two more weeks after the symptoms have been eliminated. After this period, if we need to continue with the treatment, we would recommend taking a break of one month if possible.

Differences between Papiloxyl and Papiloxyl AHCC

Depending on the pathology, your doctor will have prescribed one or the other format, the most relevant difference is the concentration of active ingredients between each one.

Papiloxyl AHCC adds derivatives of alpha-glucans, polysaccharides known for their beneficial action on the immune system.

The body's response is a stimulus in the defensive cells T and B lymphocytes, which increase in number while the macrophages are stimulated

in their opsonization and elimination of bacteria and viruses.

In this way, the neoplastic cells decrease and are progressively more controlled.

Active Hexose Correlated Compound (AHCC) has been the subject of more than 200 clinical studies.

Warnings and contraindications

It is contraindicated in pregnant and breastfeeding women. Minors are also not allowed unless specifically indicated by a specialist.

People who are immunocompromised or have severe health problems should also consult a specialist.

What is the composition of AHCC Papiloxyl?

3 capsules                      6 capsules

1500mg AHCC                 3000mg AHCC

40mg Vitamin C             80mg Vitamin C

Shiitake mushroom extract.
Supplement patented by Amino up Japan, manufactured in Japan using a proprietary liquid culture system.
Rich in easily absorbable alpha glucan polysaccharides.

vph, human papillomavirus, ahcc, hpv, cervix.

STUDIES

Clinical study.

Design: Randomized, double-blind, placebo-controlled study.
Subject: 41 patients persistently infected with high-risk HPV for at least 2 years.
Groups: AHCC® + placebo for 6 months each (n=22) and placebo for 12 months (n=19).
Dose: AHCC® 3 g/day.
Endpoints: Clearance of HPV infection, number of T cells.

Outcome
After AHCC® intake for 6 months, about 60% of patients infected with high-risk HPV showed resolution of infection. AHCC® supplementation also increased T cell count, indicating that AHCC® may clear HPV by modulating immunity.

References

1. Harris RWC, Brinton LA, Cowdell RH, Skegg DC, Smith PG, Vessey MP, et al. Characteristics of Women With Dysplasia or Carcinoma in Situ of the Cervix Uteri.Br J Cancer (1980) 42:359–69. doi: 10.1038/bjc.1980.

2. Furumoto H, Irahara M. Human Papillomavirus (HPV) and Cervical Cancer. The Journal of Medical Investigation: JMI. (2002) 49(3-4):124–33.

3. Schiffman M, Wheeler CM, Castle PE. Human Papillomavirus DNA Remains Detectable Longer Than Related Cervical Cytologic Abnormalities. J Infect Dis (2002) 186:1169–72. doi9: 10.1128/JCM.42.2.505-511.2004.

4. About HPV, Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/hpv/parents/about-hpv.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fhpv%2Fparents%2Fwhatishpv.html Accessed 9/13/19.

5. Sexually Transmitted Diseases (STDs). Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/std/hpv/default.htm accessed 9/17/19.

6. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A Controlled Trial of a Human Papillomavirus Type 16 Vaccine. NJMED (2002) 347(21):1645–51. doi: 10.1056/NEJMoa020586.

7. Von Krogh G, Held berg D. Self-Treatment Using 0.5% Podophyllotoxin Cream of External Genital Condylomata Acuminate in Women. A Placebo Controlled, Double Blind Study. Sex Transm Dis (1992) 19(3):170–4. doi: 10.1097/00007435-199205000-00012.

8. Beutner KR, Conant MA, Friedman-Kien AE, Conant MA, Illeman M, Thisted RA, et al. Patient-Applied Podofilox for Treatment of Genital Warts. Lancet (1989) 1(8642):831–4. doi: 10.1016/S0140-6736(89)92282-4.

9. Uno K, Kosuna K, Sun B, Fujii H, Wakame K, Chikumaru S, et al. Active Hexose Correlated Compound (AHCC) Improves Immunological Parameters and Performance Status of Patients With Solid Tumors. Biotherapy (2000) 14:303–9. doi: 10.4162/nrp.2015.9.2.129.

10. Gao Y, Zhang D, Sun B, Fujii H, Kosuna K, Yin Z. Active Hexose Correlated Compound Enhances Tumor Surveillance Through Regulating Both Innate and Adaptive Immune Responses. Cancer Immunol Immunother (2006) 55:1258–66. doi: 10.1007/s00262-005-0111-9.

11. Miura T, Kitadte K, Nishioka H, Wakame K. Basic and Clinical Studies on Active Hexose Correlated Compound. In: Bagchi D, Lau FC, Ghosh DK, editors. Biotechnology in Functional Foods and Nutraceuticals. London, UK: CRC Press Taylor and Francis Group (2010). p. 51–9.

12. Hirose A, Sato E, Fujii H, Suna B, Nishiokaa H, Aruom OI, et al. The Influence of Active Hexose Correlated Compound (AHCC) on Cisplatin-Evoked Chemotherapeutic and Side Effects in Tumor-Bearing Mice. Toxicol Appl Pharmacol (2007) 222:152–8. doi: 10.1016/j.taap.2007.03.031.

13. Ishibashi H, Ikeda T, Tansho S, Ono Y, Yamazaki M, Sato A, et al. Prophylactic Efficacy of a Basidiomycetes Preparation AHCC Against Lethal Opportunistic Infections in Mice. Yakugaku Zasshi (2000) 120:715–9. doi: 10.1248/yakushi1947.120.8_715.

14. Hunter RJ, Fujii H, Wakame K, Gaikwad A, Wolf JK, Smith JA. Evaluation of Active Hexose Correlated Compound (AHCC) in Combination With PEGylated Liposomal Doxorubicin for Treatment of Ovarian Cancer. Int J Appl Res Natural Products (2011) 4(3):6–11. Available at: http://www.doaj.org/doaj?func=openurl&issn=19406223&genre=journal.

15. Muthén LK, Muthén BO. (1998-2011). Mplus User's Guide. Sixth Edition. Los Angeles, CA: Muthén & Muthén (2014).

16. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural History of Cervicovaginal Papillomavirus Infection in Young Women. N Engl J Med (1998) 338(7):423–8. doi: 10.1056/NEJM199802123380703.

17. Smith JA, Mathew L, Gaikwad A, Rech B, Burney MN, Faro JP, et al. From Bench to Bedside: Evaluation of AHCC Supplementation to Modulate the Host Immunity to Clear High-Risk Human Papillomavirus Infections. Front Oncol (2019) 9:173. doi: 10.3389/fonc.2019.00173.

18. Doorbar J. Host Control of Human Papilloma Virus Infection and Disease. Best Prac Res Clin Obstet Gynecol (2018) 47:27–41. doi: 10.1016/j.bpobgyn.2017.08.001.

19. Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, et al. Blockage of Chronic Type I Interferon Signaling to Control Persistent LCMV Infection. Science (2013) 340:202–7. doi: 10.1126/science.1235208.

20. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KCF, Welch M, et al. Persistent LCMC Infection is Controlled by Blockade of Type I Interferon Signaling. Science (2013) 340:207–11. doi: 10.1126/science.1235214.

21. Roopngam PE, Sralongrua T, HuayKra A. Increased Response of Human T-Lymphocytes by Dendritic Cells Pulsed With HPV16E7 and Pleurotus Sajor-Caju-β-Glucan (PBG). Iran J Immunol (2018) 15(4):246–55. doi: 10.22034/IJI.2018.39394.

Warning

This and other similar products can be found at:

Health

Our physical and mental health is very important for the development of our daily activities. Being in good health also means being free from disease or illness.

Sexual health

Sexual health is an important part of our life. Good sexual health means being careful with ourselves and respectful of others.